Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir

Antiviral Research

Volumn 58, Issue 3, 2003, Pages 209-215

  Andersen, Jeanette Hammer ^a   Jenssen, Håvard ^a   Gutteberg, Tore Jarl ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antiviral; HSV; Lactoferricin; Lactoferrin; Synergy

Indexed keywords

ACICLOVIR; LACTOFERRICIN B; LACTOFERRIN;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS RESISTANCE; VIRUS STRAIN;

BOVINAE; FUNGI; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2;

EID: 0037721339     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00214-0     Document Type: Article

References (32)

1. Aboudy Y., Mendelson E., Shalit I., Bessalle R., Fridkin M. Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2. Int. J. Pept. Protein Res. 43:1994;573-582.
2. Andersen J.H., Osbakk S.A., Vorland L.H., Traavik T., Gutteberg T.J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51:2001;141-149.
3. Baker E.N., Baker H.M., Kidd R.D. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem. Cell Biol. 80:2002;27-34.
4. Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K., Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta. 1121:1992;130-136.
5. Bellamy W., Wakabayashi H., Takase M., Kawase K., Shimamura S., Tomita M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. 182:1993;97-105.
6. Bhimani R.S., Vendrov Y., Furmanski P. Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J. Appl. Microbiol. 86:1999;135-144.
7. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
8. Coen D.M. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol. 2:1994;481-485.
9. Daher K.A., Selsted M.E., Lehrer R.I. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60:1986;1068-1074.
10. Gutteberg T.J., Rokke O., Andersen O., Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand. J. Infect. Dis. 21:1989;709-715.
11. Hammer, J., Haaheim, H., Gutteberg, T.J., 2000. Bovine lactoferrin is more efficient than bovine lactoferricin in inhibiting HSV-I/II replication in vitro. In: Shimazaki, K. (Ed.), Lactoferrin: Structure, Functions and Application. Elsevier Science, Amsterdam, pp. 239-243.
12. Harmsen M.C., Swart P.J., de Bethune M.P., Pauwels R., De Clercq E., The T.H., Meijer D.K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172:1995;380-388.
13. Hasegawa K., Motsuchi W., Tanaka S., Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol. 47:1994;73-85.
14. Hoek K.S., Milne J.M., Grieve P.A., Dionysius D.A., Smith R. Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob. Agents Chemother. 41:1997;54-59.
15. Hwang P.M., Zhou N., Shan X., Arrowsmith C.H., Vogel H.J. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry. 37:1998;4288-4298.
16. Ikeda M., Nozaki A., Sugiyama K., Tanaka T., Naganuma A., Tanaka K., Sekihara H., Shimotohno K., Saito M., Kato N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 66:2000;51-63.
17. Kuipers M.E., de Vries H.G., Eikelboom M.C., Meijer D.K., Swart P.J. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43:1999;2635-2641.
18. Lehrer R.I., Daher K., Ganz T., Selsted M.E. Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J. Virol. 54:1985;467-472.
19. Marchetti M., Longhi C., Conte M.P., Pisani S., Valenti P., Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29:1996;221-231.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
21. Ourth D.D., Lockey T.D., Renis H.E. Induction of cecropin-like and attacin-like antibacterial but not antiviral activity in Heliothis virescens larvae. Biochem. Biophys. Res. Commun. 200:1994;35-44.
22. Shau H., Kim A., Golub S.H. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J. Leukoc. Biol. 51:1992;343-349.
23. Siciliano R., Rega B., Marchetti M., Seganti L., Antonini G., Valenti P. Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection. Biochem. Biophys. Res. Commun. 264:1999;19-23.
24. Tamamura H., Kuroda M., Masuda M., Otaka A., Funakoshi S., Nakashima H., Yamamoto N., Waki M., Matsumoto A., Lancelin J.M. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II) determined by nuclear magnetic resonance. Biochim. Biophys. Acta. 1163:1993;209-216.
25. Tomita M., Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci. 74:1991;4137-4142.
26. van Der Strate B.W., Beljaars L., Molema G., Harmsen M.C., Meijer D.K. Antiviral activities of lactoferrin. Antiviral Res. 52:2001;225-239.
27. Viani R.M., Gutteberg T.J., Lathey J.L., Spector S.A. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS. 13:1999;1273-1274.
28. Vorland L.H. Lactoferrin: a multifunctional glycoprotein. APMIS. 107:1999;971-981.
29. Weinberg E.D. Human lactoferrin: a novel therapeutic with broad spectrum potential. J. Pharm. Pharmacol. 53:2001;1303-1310.
30. Whitley, R.J., 1995. Herpes simplex viruses. In: Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), Fields Virology. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 2461-2509.
31. Yasin B., Pang M., Turner J.S., Cho Y., Dinh N.N., Waring A.J., Lehrer R.I., Wagar E.A. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;187-194.
32. Yoo Y.C., Watanabe S., Watanabe R., Hata K., Shimazaki K., Azuma I. Bovine lactoferrin and lactoferricin a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88:1997;184-190.